Paradigm Capital Management LLC NV Trims Holdings in Pfizer Inc. $PFE

Paradigm Capital Management LLC NV trimmed its position in Pfizer Inc. (NYSE:PFE) by 29.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,981 shares of the biopharmaceutical company’s stock after selling 25,097 shares during the quarter. Pfizer comprises approximately 1.6% of Paradigm Capital Management LLC NV’s holdings, making the stock its 20th biggest position. Paradigm Capital Management LLC NV’s holdings in Pfizer were worth $1,545,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. purchased a new stake in Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter worth approximately $27,000. North Capital Inc. bought a new position in Pfizer in the 1st quarter worth approximately $28,000. Finally, Bayforest Capital Ltd bought a new position in Pfizer in the 1st quarter worth approximately $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.3%

Shares of PFE opened at $25.07 on Tuesday. The company has a market cap of $142.54 billion, a PE ratio of 13.34, a P/E/G ratio of 0.89 and a beta of 0.52. The business has a fifty day moving average of $24.62 and a 200 day moving average of $24.41. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $0.60 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analysts Set New Price Targets

Several research firms have weighed in on PFE. Wolfe Research upped their price target on Pfizer from $22.00 to $23.00 and gave the stock an “underperform” rating in a research note on Wednesday, April 30th. TD Cowen dropped their price target on Pfizer from $32.00 to $28.00 and set a “hold” rating for the company in a research note on Tuesday, April 22nd. Leerink Partners dropped their price target on Pfizer from $28.00 to $26.00 and set a “market perform” rating for the company in a research note on Wednesday, April 30th. The Goldman Sachs Group upped their price target on Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Finally, Jefferies Financial Group upped their price target on Pfizer from $32.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.